Read the signal. Shape what comes next.Updated 21 Oct 2026, 17:06 UTC · Get the Signal Brief
Higher Ed Signal

Research, innovation and assessment · France

ANR pre-announces ERA4Health 2027 call requiring nano-diagnostics to beat existing tests

France's national research agency has signalled a translational call, NanoDiagNCD, for nanotechnology-based diagnostics for non-communicable diseases. Proposals must show measurable gains over current approaches and plan for clinical adoption.

By Scott James, Research and Innovation Editor
Wide paved plaza with a grid-like pattern of light and dark tiles on a French university campus, with low modern buildings, evergreen trees and snow-capped Alpine peaks under a partly cloudy sky.
Photo: Guilhem Vellut from Annecy, France / Wikimedia Commons, CC BY 2.0

The Agence nationale de la recherche (ANR) has published a pre-announcement for an ERA4Health 2027 call, NanoDiagNCD, on diagnostic tools for non-communicable diseases.

According to ANR, the call will support translational research that applies nanotechnology, alone or with key enabling technologies, to develop or validate diagnostic and theranostic tools built on solid scientific evidence.

ANR said projects must define and validate performance thresholds against existing diagnostic approaches, showing added value on at least one criterion such as sensitivity, specificity, accessibility, cost, patient comfort, invasiveness or safety.

The agency said requirements for clinical translation and adoption, including scale-up, production, standardisation, cost-effectiveness, regulatory requirements and interoperability, must be anticipated at every stage of the research.

Why it matters

Applicants will need to benchmark their tools against existing diagnostics on defined performance criteria, so teams considering a bid face an explicit comparative-evidence requirement rather than a proof-of-concept standard alone.

The stated scope spans the care pathway, from prevention and early detection to disease monitoring, treatment choice and assessment of adverse effects, which may bring a range of health-related research groups within reach of the call.

Editor’s view

Scott James, Research and Innovation Editor

What stands out in ANR's description is how concrete the success test is: proposals must set performance thresholds and show added value over current diagnostics on named criteria, while also accounting for production, standardisation, regulation and cost-effectiveness. For research offices, that gives a clear checklist against which to assess whether a candidate project is ready to compete.

Much remains to be confirmed. As a pre-announcement, it does not settle how much funding is available, when proposals are due or how partner eligibility will work. Leaders deciding whether to invest preparation time will want to watch for the full call text before committing significant resources.

What to watch

  • Publication of the full NanoDiagNCD call following this pre-announcement, and the budget, deadlines and eligibility rules it sets.
  • Which funders and countries take part alongside ANR in the ERA4Health 2027 call.